Pharming Group N.V. (LON:0QCO)

Pharming Group Statistics

Total Valuation

Pharming Group has a market cap or net worth of GBP 518.02 million. The enterprise value is 528.55 million.

Market Cap	518.02M
Enterprise Value	528.55M

Important Dates

The next estimated earnings date is Thursday, July 31, 2025.

Earnings Date	Jul 31, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	685.15M
Shares Outstanding	n/a
Shares Change (YoY)	+2.22%
Shares Change (QoQ)	-9.59%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	670.71M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.09
PB Ratio	3.11
P/TBV Ratio	8.91
P/FCF Ratio	131.44
P/OCF Ratio	110.01
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 35.07, with an EV/FCF ratio of 134.11.

EV / Earnings	-48.39
EV / Sales	2.06
EV / EBITDA	35.07
EV / EBIT	55.10
EV / FCF	134.11

Financial Position

The company has a current ratio of 2.76, with a Debt / Equity ratio of 0.55.

Current Ratio	2.76
Quick Ratio	2.00
Debt / Equity	0.55
Debt / EBITDA	5.86
Debt / FCF	23.40
Interest Coverage	1.10

Financial Efficiency

Return on equity (ROE) is -6.78% and return on invested capital (ROIC) is 2.38%.

Return on Equity (ROE)	-6.78%
Return on Assets (ROA)	1.99%
Return on Invested Capital (ROIC)	2.38%
Return on Capital Employed (ROCE)	4.14%
Revenue Per Employee	614,418
Profits Per Employee	-27,036
Employee Count	404
Asset Turnover	0.76
Inventory Turnover	0.61

Taxes

In the past 12 months, Pharming Group has paid 8.22 million in taxes.

Income Tax	8.22M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +10.63% in the last 52 weeks. The beta is 0.54, so Pharming Group's price volatility has been lower than the market average.

Beta (5Y)	0.54
52-Week Price Change	+10.63%
50-Day Moving Average	0.93
200-Day Moving Average	0.84
Relative Strength Index (RSI)	44.12
Average Volume (20 Days)	125,632

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Pharming Group had revenue of GBP 248.22 million and -10.92 million in losses. Loss per share was -0.02.

Revenue	248.22M
Gross Profit	220.88M
Operating Income	10.43M
Pretax Income	-2.83M
Net Income	-10.92M
EBITDA	13.12M
EBIT	10.43M
Loss Per Share	-0.02

Balance Sheet

The company has 83.03 million in cash and 92.22 million in debt, giving a net cash position of -9.19 million.

Cash & Cash Equivalents	83.03M
Total Debt	92.22M
Net Cash	-9.19M
Net Cash Per Share	n/a
Equity (Book Value)	166.63M
Book Value Per Share	0.25
Working Capital	105.70M

Cash Flow

In the last 12 months, operating cash flow was 4.71 million and capital expenditures -767,798, giving a free cash flow of 3.94 million.

Operating Cash Flow	4.71M
Capital Expenditures	-767,798
Free Cash Flow	3.94M
FCF Per Share	n/a

Margins

Gross margin is 88.98%, with operating and profit margins of 4.20% and -4.40%.

Gross Margin	88.98%
Operating Margin	4.20%
Pretax Margin	-1.14%
Profit Margin	-4.40%
EBITDA Margin	5.29%
EBIT Margin	4.20%
FCF Margin	1.59%

Dividends & Yields

Pharming Group does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.22%
Shareholder Yield	n/a
Earnings Yield	-2.11%
FCF Yield	0.76%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on March 5, 2013. It was a reverse split with a ratio of 0.1.

Last Split Date	Mar 5, 2013
Split Type	Reverse
Split Ratio	0.1

Scores

Pharming Group has an Altman Z-Score of 2.19 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.19
Piotroski F-Score	6